Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease.

Kim, Daehong; Park, Giljun; Huuhtanen, Jani; Lundgren, Sofie; Khajuria, Rajiv K; Hurtado, Ana M; Muñoz-Calleja, Cecilia; Cardeñoso, Laura et al. · Nat Commun · 2020

basic_science · Level V

Where this comes from

Abstract

Graft versus host disease (GvHD) is the main complication of allogeneic hematopoietic stem cell transplantation (HSCT). Here we report studies of a patient with chronic GvHD (cGvHD) carrying persistent CD4<sup>+</sup> T cell clonal expansion harboring somatic mTOR, NFKB2, and TLR2 mutations. In the screening cohort (n = 134), we detect the mTOR P2229R kinase domain mutation in two additional cGvHD patients, but not in healthy or HSCT patients without cGvHD. Functional analyses of the mTOR mutation indicate a gain-of-function alteration and activation of both mTORC1 and mTORC2 signaling pathways, leading to increased cell proliferation and decreased apoptosis. Single-cell RNA sequencing and real-time impedance measurements support increased cytotoxicity of mutated CD4<sup>+</sup> T cells. High throughput drug-sensitivity testing suggests that mutations induce resistance to mTOR inhibitors, but increase sensitivity for HSP90 inhibitors. Our findings imply that somatic mutations may contribute to aberrant T cell proliferations and persistent immune activation in cGvHD, thereby paving the way for targeted therapies.

Medical subject headings